Beijing SynsorBio Technology Co., Ltd

Founded in June 2020, SynsorBio is driven by the vision of Nucleic Acid detection at your fingertips. Leveraging our two proprietary technology platforms — CRISPR/Cas detection and NGS sample preparation — we deliver cutting-edge diagnostic solutions to meet diverse clinical and research needs.

I. CRISPR/Cas-Based Detection Platform

Our CRISPR/Cas detection platform offers comprehensive development solutions across multiple product formats, including:

• High-throughput all-in-one systems
• Molecular POCT (Point-of-Care Testing) platforms
• CRISPR multiplex detection systems

We specialize in the development and application of emerging molecular biology technologies and point-of-care diagnostic solutions, enabling rapid, accurate testing where it matters most.

II. NGS Sample Preparation Platform

Our NGS platform provides end-to-end solutions — integrating both reagents and instruments — for upstream sample processing in high-throughput sequencing. Designed for speed, flexibility, and efficiency, our solutions seamlessly adapt to a wide range of application scenarios.